title: Identification of candidate genes for human retinal degeneration loci using differentially expressed genes from mouse photoreceptor dystrophy models.
abstract: OBJECTIVE
  Retinal degeneration (RD) is a complex mechanism that appears to involve many biologic processes including oxidative stress, apoptosis, and cellular remodeling. Currently there are 51 mapped, but not identified, RD human disease loci.
  
  
  METHODS
  To assign possible disease genes to RD loci, we have used a comparative genomics procedure that incorporates microarray gene expression data of three independent mouse models for photoreceptor dystrophy (rd1, rd2, and constant light-damage in BALB/c mice), human ortholog data, and databases of known chromosomal locations involved in human RD. Immunohistochemistry and enzyme activity assays were used to further characterize a candidate gene product.
  
  
  RESULTS
  Our analysis yielded candidate genes for four mapped, but unsolved, human chromosomal locations and confirmed two previously identified monogenic disease loci for human RD, thus validating our approach. PLA2G7 (phospholipase A2, group VII; PAF-AH, Lp-PLA2), a candidate for a dominant form macular dystrophy (Benign Concentric Annular Macular Dystrophy [BCMAD]), was selected for further study. The PLA2G7 enzyme is known to mediate breakdown of oxidatively damaged phospholipids, a contributor to oxidative stress in the retina. PLA2G7 protein was enriched in mouse photoreceptor inner and outer segments. In the rd1, rd2, and BALB/c mice exposed to constant light, retinal tissue activity levels, but not plasma levels, were significantly reduced at the onset of photoreceptor cell death.
  
  
  CONCLUSIONS
  We have shown that this comparative genomics approach verified existing RD genes as well as identified novel RD candidate genes. The results on the characterization of the PLA2G7 protein, one of the novel RD genes, suggests that retinal tissue PLA2G7 levels may constitute an important risk factor for BCMAD. In summary, this reverse mapping approach, using accepted mouse models of human disease and known human RD loci, may prove useful in identifying possible novel disease candidates for RD and may be applicable to other human diseases.
authors.affiliation: Department of Physiology and Neuroscience, Medical University of South Carolina, Charleston, SC 29425, USA.
authors.forename: Christina
authors.initials: C
authors.lastname: Demos
authors.forename: Mausumi
authors.initials: M
authors.lastname: Bandyopadhyay
authors.forename: Bärbel
authors.initials: B
authors.lastname: Rohrer
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D015536:Down-Regulation; D020869:Gene Expression Profiling; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D054467:Phospholipases A2 / Q000235:genetics / Q000378:metabolism; D020419:Photoreceptor Cells, Vertebrate / Q000473:pathology*; D021381:Protein Transport; D012162:Retinal Degeneration / Q000201:enzymology / Q000235:genetics*; D015854:Up-Regulation
chemical_list: D054467:Phospholipases A2
references.citation: Science. 2005 Apr 15;308(5720):419-21
references.pmid: 15761120
references.citation: Nat Genet. 2004 Nov;36(11):1153-8
references.pmid: 15514669
references.citation: Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1293-301
references.pmid: 16565360
references.citation: Ann N Y Acad Sci. 1999;893:282-5
references.pmid: 10672249
references.citation: J Neurosci. 1999 Oct 15;19(20):8919-30
references.pmid: 10516311
references.citation: Nature. 1989 Mar 2;338(6210):70-3
references.pmid: 2918924
references.citation: Arch Ophthalmol. 2004 Apr;122(4):598-614
references.pmid: 15078679
references.citation: Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2737-46
references.pmid: 15277499
references.citation: Exp Eye Res. 2006 Aug;83(2):380-9
references.pmid: 16626700
references.citation: Science. 1974 Nov 1;186(4162):449-51
references.pmid: 4369896
references.citation: Prog Retin Eye Res. 2001 Nov;20(6):705-32
references.pmid: 11587915
references.citation: Neuron. 1991 Jan;6(1):61-70
references.pmid: 1986774
references.citation: Science. 2005 Apr 15;308(5720):421-4
references.pmid: 15761121
references.citation: Hum Mol Genet. 2008 May 1;17(9):1318-28
references.pmid: 18204052
references.citation: Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):974-8
references.pmid: 8302876
references.citation: Invest Ophthalmol Vis Sci. 2004 Apr;45(4):1247-58
references.pmid: 15037594
references.citation: Invest Ophthalmol Vis Sci. 2003 May;44(5):2211-20
references.pmid: 12714663
references.citation: Invest Ophthalmol Vis Sci. 1995 Feb;36(2):263-75
references.pmid: 7843898
references.citation: Science. 2005 Apr 15;308(5720):385-9
references.pmid: 15761122
references.citation: BMC Genomics. 2004 Jul 29;5(1):50
references.pmid: 15283859
references.citation: Clin Exp Ophthalmol. 2007 Jul;35(5):473-85
references.pmid: 17651254
references.citation: Exp Eye Res. 2003 Jan;76(1):125-9
references.pmid: 12589782
references.citation: PLoS Biol. 2004 Sep;2(9):E247
references.pmid: 15226823
references.citation: J Immunol. 2006 Aug 1;177(3):1872-8
references.pmid: 16849499
references.citation: Curr Atheroscler Rep. 2007 Aug;9(2):97-103
references.pmid: 17877917
references.citation: N Engl J Med. 2007 Aug 9;357(6):553-61
references.pmid: 17634448
references.citation: Invest Ophthalmol Vis Sci. 2003 Apr;44(4):1426-34
references.pmid: 12657576
references.citation: Curr Opin Genet Dev. 1994 Jun;4(3):427-38
references.pmid: 7919921
references.citation: Biostatistics. 2003 Jul;4(3):465-77
references.pmid: 12925512
references.citation: J Neurosci. 2005 May 4;25(18):4540-9
references.pmid: 15872101
references.citation: Exp Eye Res. 2007 Jan;84(1):82-91
references.pmid: 17069800
references.citation: Novartis Found Symp. 2004;255:17-27; discussion 27-36, 177-8
references.pmid: 14750594
references.citation: Invest Ophthalmol Vis Sci. 2005 Jan;46(1):349-57
references.pmid: 15623795
references.citation: Nat Genet. 2006 Apr;38(4):458-62
references.pmid: 16518403
references.citation: Eur J Hum Genet. 2003 May;11(5):420-3
references.pmid: 12734549
references.citation: Clin Immunol. 2003 Jun;107(3):140-51
references.pmid: 12804527
references.citation: J Biol Chem. 2004 Oct 1;279(40):41903-10
references.pmid: 15218024
references.citation: FASEB J. 2005 Oct;19(12):1683-5
references.pmid: 16099945
references.citation: J Clin Endocrinol Metab. 2005 May;90(5):3100-5
references.pmid: 15713711
references.citation: Hum Genet. 2005 Dec;118(3-4):356-65
references.pmid: 16189710
references.citation: Am J Hum Genet. 2000 May;66(5):1522-30
references.pmid: 10733466
references.citation: Curr Opin Lipidol. 2008 Jun;19(3):289-94
references.pmid: 18460921
references.citation: Mol Vis. 2007 Feb 28;13:287-92
references.pmid: 17356515
references.citation: Bioessays. 2001 Jul;23(7):605-18
references.pmid: 11462214
references.citation: J Biol Chem. 1987 Mar 25;262(9):4223-30
references.pmid: 3558407
references.citation: Semin Immunol. 1998 Oct;10(5):355-61
references.pmid: 9799710